Topics:

Monoclonal Anti-CD20 Antibody Rituximab for Treatment of CD20-Positive Hodgkin’s Lymphoma: The German Experience

Monoclonal Anti-CD20 Antibody Rituximab for Treatment of CD20-Positive Hodgkin’s Lymphoma: The German Experience

Response rates up to 50% have been observed in patients with relapsed CD20-positive non-Hodgkin’s lymphoma after treatment with the chimeric monoclonal anti-CD20 antibody rituximab (Rituxan). The malignant cell population in lymphocyte-predominant Hodgkin’s disease (LPHD) also expresses the CD20 antigen in high density, while only 20% of all Hodgkin-Reed-Sternberg cells in classical Hodgkin’s disease (HD) are CD20 positive.

This phase II study investigates the safety and efficacy of 4 × 375 mg/m2 rituximab in patients with relapsed LPHD or CD20-positive classical HD. Eligibility criteria included expression of the CD20 antigen on more than 30% of all malignant cells; histologic slides had to be reviewed by a reference panel.

Six patients (five males, one female) have been treated so far (as of June 2000). Median age was 37 years (range: 26 to 52 years); median time since first diagnosis was 3 years (range: 1.7 to 5.9 years). All patients had at least one prior chemotherapy: all five patients with LPHD were in first relapse, while the HD patient had been treated with two previous therapeutic regimens, including autologous peripheral stem cell transplantation. With 375 mg/m2 rituximab weekly × 4 toxicity was moderate and transient. Side effects comprised chills, fever, and hypotension. At 5 months of median follow-up (range: 1 to 9 months), response rates were 100% (4 complete remissions, 1 partial remission) for patients with relapsed LPHD. The patient with the relapsed classical HD is in complete remission 10 months after completion of therapy.

CONCLUSION: Administration of rituximab to patients with LPHD or CD20-positive classical HD is safe and feasible. These preliminary data suggest high efficacy with response rates up to 100%. Longer follow-up is necessary. Because the number of patients with LPHD and CD20-positive classical HD is small, international cooperation has been started.

Click here to read Dr. Bruce Cheson's commentary on this abstract.

 
Loading comments...
Please Wait 20 seconds or click here to close